you Okay, Philippe. thank
go slide the please. next Let’s to
an update clinical CBXXXX on start Let’s with program. the
be healthy safety, X-week NFALD stage CBXXXX activity our which a XA and press this getting This we in Phase possible mentioned Phase back and showed the establish of of obese with endpoints volunteers to on As as is as that obesity. dose-range in starts Xb the by the of study to It the with CBXXXX NASH a into in of assessing tolerability subjects to and the the CBXXXX. an finding pharmacokinetics will as clinic continue relevant clinical reminder, slide are study. stage goal initial design focus followed against soon release,
calls, site address or on phase to indurations escalation was study. during were discussed observed mild, have at suspended the previous the we bumps as the persistent that the of but the Now unexpectedly dose study injection
mitigate also call We on to announced a FDA we that December plan issue. intended the to clinical our investor have submitted
talk process. about the let’s So, of status that
please. slide Next
to therefore and higher situations of situation Now, is involving the to related FDA the adverse priority. as for urgency have for request comment respond serious know, a timeline you to may effects the
hold clinical and the were hoping we imposed recall that a seeing are subject although is which external FDA here we not response So quick are factors. agency, and feedback, timeline on an slower of for to some we the from internal course
its Now X, opportunity prominent have on with FDA experts discuss been also CohBar for our feedback, had expediting clinical study, to goal March our clinical and plan first with the parallel with but discussing we in finally the lengthy of regulatory FDA resuming awaiting to several the FDA, plan process.
please. next Let’s slide go to our
these Dr. Leyden, of who at advisers So, professor MD, Dermatology among Pennsylvania. is of the is James University emeritus
data concern. significant no adviser in safety is does Dr. otherwise there depot Phase are our these He Phase XX in that in He as more localized concurs to X of to agencies assessment trials. Leyden the dissipate, and that has study and been well of but to concluded U.S. an clinical and regulatory involved observed issue. preclinical that as represent years detail slow been Now, a is not due has with European X reviewed has safety bumps also studies our safety has a than drug
Now, call our with participated FDA. Leyden also on Dr. recent
go to next the Let’s slide.
the about next let’s talk So, steps here.
Phase recent discussion on that to complete some of subjects Xa information are with them enrollment remaining resume regulatory of submitting and by finding. steps to that now that we begins We to to hand. dose have the we FDA, follow-on following the the healthy resuming plan clearance As additional study
we would the subjects initiate selection, dose Phase stage. Xb obese, enroll and Following the NFALD
to Now, although soon get when the to concluded, we cannot clinic process resume the poised with be and into possible. hope FDA back as the as be we are certain will study
but also we post of on and clinicaltrials.gov. expect a We expect obviously clarity we a development, about on once the CohBar there timelines to going more have updated talked the we CohBar’s study at Though final provide of to pipeline. design is the XXXX external to attention status rest have lot
research enhanced focus of peptide additional of broader to began in the research effort additional cell-based year, analogs That assay with efforts has we CohBar Following that to capabilities the design adding the optimization the middle expanded growing portfolio biological mitochondrially-encoded internal repertoire our evaluation on successful included of financing our lab. and expand research last peptides. to in novel an our synthesis, related
new state-of-the-art to different are we aid characterizing external has the and use leads areas. added for metabolism effort have to number analytical We in-house target of included and of That in broad activity peptide screens capability harnessing properties physical screening new two look in external a approaches. new
The first approach of this screening with receptors known cell slide target-based as on activity functionality. involves surface
or structural goal a peptides peptides the to in this specifically target the their potential slide. other on look processes separately target the of new action of send shown carried is screened a receptor to the related reminder, can peptides broad molecules. The the individual blocking uses here target their action these analog high identified both opportunities act known molecules. this apart format enhanced of an itself type that and by a may change so look other cells into signals surface cell. surface directly very within signaling able from human that the assay signaling receptor process of of selective against can of of receptors. mechanism find that proteins activated, and effects a spectrum the receptor they effect signal analogs in tease the to as as assays, the to left are identify indications. of The of activate receptors on the of be on composed that interaction cellular of Now, like example the We cell activity. the in the and placed regulate can cell-based unlock leading screening sit levels expressing This are natural be within uncover downstream receptors process of and to we at peptide changes the the our cellular activity messages entire to depth cell are is thereby signal compare that a cellular selective for are therapeutic a as that use this, or list they in signal. further we approach started families knowing throughput The When can at simultaneously inhibit Once activator receivers and cell can the alters specific additional helps cells those
Next slide please.
effect employ where second type The what of is looking screening we are with at on we than externally we screening, the call target. rather the the interaction the peptide more of cell phenotypic its
protein in of clinical slide, cellular significant in relevance. processes, induces certain wide-ranging the systems. a changes a disease we So, fibrosis that example, The range a maybe protein peptide in in specific to analog at screens, things related other relevant very clinically biomarkers changes like this for can cell-based in broad increases example be with levels biomarkers shown phenotypic these and we these wide inflammation, in processes. range In of known human looking see
So, affected opportunities the that helps and by biomarkers again, potentially slide, the for Go to are therapeutic their reveals identifying areas. peptides our mechanism uncover of next to new specific please. additional action
we’re these unexpected peptide applying among see new screens Now continue external and mitochondrial activity our to novel analogs. and
that a analogs advanced seen cell academic By we’ve activity CBXXXX beneficial I’ve actively activity of of animal age-related demonstrated receptor subject of that the target in the arena in understanding the glycemic we’re example, the action receptor to of X on one type in so peptide far are using key models we a types and new that and family of at already in currently their peptide of a pharma optimizing key have that screens, of to in their play intense diseases. unrelated of mechanism significantly surface other class. exploring control diabetes, For this screening research described, have the diabetes of appears completely labs number effects role
potentially that peptide engage important an of entirely discovery possibility receptor. new the this class So, of agents unlocks this
our Now, presentation an a meeting recent this for scheduled we that year. for as is later breakthrough, major on a at result abstract this findings submitted have of scientific
please. slide, Next
based So, beyond X seeing. are prioritizing we arena, what we activities are on diabetes type the our research
For in our area. for with our for resources. discovery our path mitochondrially peptides field on Obviously, in than potential cancers. assessment expanding to leads evaluation to we that to from is looking are in models we’re and extending earlier we here the cases, many with proof-of-concept. animal such early in initial of research most example, peptide the internal the An more look hope here in stage opportunities can models. we’re druggable broad fibrosis Behind activity oncology, encoded there uncover broad animal of that, antiproliferative specific more activities entirely explore potent further a are for analogs CohBar we disease the example screening In towards fastest rigorous at of
early we So, for return to also to research And support under CROs partner look opportunities some for collaboration. use to Philippe. stage continue that, stage examples of will these external the and a I’ll with
